A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

Table 2 Demographic data and baseline characteristics of the patients

Characteristics	Placebo (n = 23)	100 mg/day 5-Loxin^® (n = 24)	250 mg/day 5-Loxin^® (n = 23)
Sex (male/female; n)	5/18	7/17	8/15
Age (years)	52.43 ± 9.65	52.37 ± 8.37	53.22 ± 8.73
Body weight (kg)	61.48 ± 10.69	61.08 ± 10.67	54.84 ± 10.19
Body mass index (kg/m²)	26.05 ± 4.29	25.91 ± 4.94	22.64 ± 4.07
Visual analog score (mm)	56.88 ± 12.04	57.05 ± 8.71	55.62 ± 9.26
Lequesne's Functional Index	12.76 ± 2.6	12.1 ± 2.76	12.04 ± 3.03
WOMAC score
Pain subscale	38.04 ± 9.7	48.08 ± 14.05	37.17 ± 13.8
Stiffness subscale	33.15 ± 13.3	31.8 ± 17.6	27.7 ± 16.8
Function subscale	41.3 ± 9.6	41.5 ± 11.1	38.6 ± 11.1

Values are expressed as mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

ISSN: 1478-6362